Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JUNE 2017. Refer to TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | regorafenib (Stivarga®) | ||
| Formulation | 40 mg film-coated tablet | ||
| Reference number | 1018 | ||
| Indication | Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib |
||
| Company | Bayer Healthcare Pharmaceuticals | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 1915 | ||
| NMG meeting date | 13/05/2015 | ||
| AWMSG meeting date | 17/06/2015 | ||
| Ratification by Welsh Government | 15/07/2015 | ||
| Date of issue | 16/07/2015 | ||
| NICE guidance | |||